The study, published in Nature Genetics, describes a clinically annotated, population-scale single-cell atlas built from bone marrow samples of 341 patients, spanning the full continuum of the disease from precursor conditions through newly diagnosed myeloma to relapsed and refractory disease after multiple lines of therapy. Using single-cell RNA sequencing enriched for plasma cells and the surrounding CD45-positive immune compartment, the researchers captured the transcriptomes of tens of thousands of individual cells, allowing them to dissect the malignant compartment cell by cell rather than averaging signals across bulk tumor tissue, which has historically masked the very heterogeneity that drives treatment failure.

Technically, the effort was formidable. Samples were processed using the MARS-seq platform and an updated version, MARS-seq2.0, with rigorous quality control on mitochondrial content, unique molecular identifier counts and detected genes. Cells were annotated through a computational pipeline combining scVI latent-space integration, uniform manifold approximation and projection embeddings, and inferCNV-based inference of copy number alterations to distinguish malignant plasma cells from their normal counterparts. The team then applied non-negative matrix factorization to decompose malignant gene expression into recurrent transcriptional programs, validated for stability through hundreds of bootstrapped iterations. This dual-layer analytical strategy allowed the investigators to separate two largely independent axes of tumor biology: what kind of myeloma a patient has, and how fast that myeloma is growing.

The first axis yielded five recurrent malignant transcriptional archetypes, designated MM1 through MM5, each corresponding to a stable pattern of gene expression anchored in distinct biological pathways. These archetypes align with known myeloma biology, including immunoglobulin heavy chain translocations such as t(11;14) with its cyclin D and BCL-2 dependencies, t(4;14) with NSD2 dysregulation, MAF and MAFB associated programs, and features reflecting unfolded protein response burden and bone marrow niche interactions. Crucially, the archetypes were not merely descriptive. They correlated with genomic features, therapeutic sensitivity patterns and clinical outcomes, and the team demonstrated that the classification could be ported to independent bulk RNA datasets, including the Blueprint cohort and the Multiple Myeloma Research Foundation’s CoMMpass cohort of treatment-naive patients, confirming that the single-cell-defined signatures retain prognostic power even when measured on standard clinical platforms.

The second axis, orthogonal to the archetypes, is a proliferative program. By scoring single-cell proliferation signatures and characterizing plasmablastic cells, the rapidly dividing precursors of antibody-secreting plasma cells, the researchers quantified the fraction of malignant cells actively cycling in each patient’s marrow. Proliferation has long been recognized as a poor prognostic marker in myeloma, measured historically by crude methods such as plasma cell labeling indices. The new work refines this concept at single-cell resolution, showing that the proportion of proliferating malignant plasma cells stratifies patients within every archetype, revealing intra-archetypal heterogeneity that earlier bulk approaches could not detect. In relapsed and refractory patients, higher proliferative fractions predicted shorter progression-free survival, and the effect persisted in multivariate Cox regression models adjusting for cytogenetic risk, age and prior treatment lines.

Combining the two axes produced an improved risk stratifier that outperformed existing molecular subtyping schemes. Patients could be placed into joint archetype-proliferation subgroups with meaningfully distinct progression-free and overall survival, and the framework added prognostic information beyond standard clinical variables including high-risk cytogenetics and chromosome 1p deletion. The validation in CoMMpass, one of the largest longitudinally followed myeloma cohorts in the world, demonstrated robustness and portability across sequencing platforms, an essential prerequisite for clinical translation. In principle, a myeloma patient’s tumor could one day be assigned to an archetype and proliferation state from a routine biopsy, guiding intensity of upfront therapy and informing decisions about transplantation, novel agents or early escalation.

Perhaps the most clinically electrifying result, however, came from the atlas’s use as a target-discovery engine. The team built a computational pipeline that ranked every protein-coding gene by a composite score integrating malignant enrichment, specificity for malignant plasma cells relative to normal plasma cells, and restriction across healthy tissues, the latter being critical to minimize off-tumor toxicity for any future immunotherapy. This screen surfaced FCRL2, an Fc receptor-like molecule with established roles in B cell biology, as a surface target expressed by malignant plasma cells but largely restricted to the B cell lineage elsewhere in the body. The atlas approach meant the researchers could verify not just that myeloma cells express FCRL2, but that expression is preserved across archetypes and proliferation states, addressing the antigen escape problem that plagues current myeloma immunotherapies.

The translational proof followed swiftly. The researchers engineered chimeric antigen receptor T cells directed against FCRL2 and tested them against myeloma cell lines with varying levels of target expression. In vitro, FCRL2-redirected CAR-T cells killed antigen-positive myeloma cells in an antigen-specific manner, with luciferase-based co-culture assays showing progressive suppression of tumor cell growth compared to non-transduced controls, and detailed immunophenotyping confirming proper CAR expression and memory-phenotype differentiation of the engineered cells. In mouse models, FCRL2-targeted CAR-T cells conferred a significant survival benefit. Given that existing myeloma immunotherapies targeting BCMA and GPRC5D eventually fail through antigen loss and relapse, a third lineage-restricted target backed by a genome-wide, single-cell-verified prioritization pipeline offers a credible path toward combination or sequential immunotherapy strategies.

For patients, the near-term significance is prognostic rather than therapeutic: an archetype and proliferation score could refine risk assessment well before relapse, when treatment decisions matter most. For the field, the study establishes a template for how population-scale single-cell atlases can move beyond description into actionable classification and target nomination. All of the underlying data, including the full scRNA-seq dataset deposited in the Gene Expression Omnibus and the analysis code released openly by the Amit lab, are publicly available, ensuring that other groups can interrogate, extend and challenge the framework. As single-cell sequencing costs fall and clinical grade assays mature, the line between research atlases and routine diagnostics grows thinner, and this myeloma atlas may be remembered as a turning point where that line was crossed for a historically intractable cancer.

Subject of Research: Single-cell transcriptomic atlas of multiple myeloma defining malignant archetypes, proliferative states, and the immunotherapy target FCRL2

Article Title: A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states

Article References: Zada, M., Kurilovich, A., Shapira, N., Wang, S.-Y., Sharet-Eshed, R., Kfir-Erenfeld, S., Schlossberg, M., Zorde, E., Asherie, N., Gur, C., Chalan, P., Shalita, R., Ben Yehuda, M., Zwicky, P., von Locquenghien, M., Ingelfinger, F., Mazuz, K., David, E., Gurevich-Shapiro, A., … Amit, I. (2026). A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states. Nature Genetics, 58(9), 2254-2269. https://doi.org/10.1038/s41588-026-02725-5

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02725-5

Keywords: multiple myeloma, single-cell RNA sequencing, transcriptional archetypes, proliferation, FCRL2, CAR-T cell therapy, risk stratification, plasma cells, Nature Genetics, precision medicine, CoMMpass cohort, target discovery